TAK, US8740602052

Takeda presents oncology data: what it means for Takeda stock

Published on 10/23/2026 at 10:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Late-stage cancer data lead Takeda's October 23 ESMO program. Takeda stock costs EUR 18.00 on October 23, 2026 at Lang & Schwarz during trading.

Pipeline and reporting dates

Takeda's oncology program includes Phase 3 data presented on October 23, 2026.
Takeda will release fiscal 2026 second-quarter results on October 29, 2026.
Takeda stock trades at EUR 18.00 at 10:02 a.m. CEST at Lang & Schwarz on October 23, 2026.
Takeda's market capitalization was USD 64.8 billion as of October 22, 2026.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda Pharmaceutical stock (ISIN US8740602052) was trading at EUR 18.00 at Lang & Schwarz on October 23, 2026 at 10:02 a.m. CEST. The company is presenting late-stage oncology data at the ESMO 2026 congress, with Phase 3 arcotatug tavatecan data scheduled for October 23, according to Business Wire.

What does the pipeline mean?

The immediate value of the ESMO program is clinical validation rather than reported revenue. Takeda said the congress would feature late-breaking data from the Phase 3 G-HOPE-001 study of arcotatug tavatecan in previously treated advanced gastric or gastroesophageal junction cancer. The program also includes two presentations on TAK-928, an investigational treatment being tested in lung cancer.

The company identifies arcotatug tavatecan and TAK-928 as investigational compounds that have not received approval from the U.S. Food and Drug Administration or other regulators. That distinction keeps the pipeline event separate from commercial sales and leaves regulatory progress as the next measurable step.

Three dates shape the story

On July 30, 2026, Takeda reported quarterly revenue of USD 7.50 billion and earnings per share of USD 0.95 against consensus of USD 7.13 billion and USD 0.41, respectively, as reported by MarketBeat. On September 22, 2026, Takeda outlined its ESMO program. On October 23, 2026, the company presented the Phase 3 oncology data.

When are the next results?

Takeda will release fiscal 2026 second-quarter results on October 29, 2026, followed by an investor webcast from 7:00 p.m. to 8:15 p.m. JST, according to Takeda. Investors will receive a new operating-period reference before the pipeline story can be weighed against fresh financial results.

Stock stays tied to upcoming evidence

Takeda's market capitalization was USD 64.8 billion as of October 22, 2026, while its 52-week range stood at USD 12.99 to USD 20.39. The combination places the oncology presentations and the October 29 results on separate tracks: one tests development potential, while the other updates the earnings base. Takeda Pharmaceutical stock was trading at EUR 18.00 at Lang & Schwarz on October 23, 2026 at 10:02 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Takeda stock.